Zanamivir (Dectova®) which is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when the patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/08/2019|
|Rapid review completed||17/10/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that zanamivir (Dectova®) be considered for reimbursement*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations; November 2019